Agios Pharmaceuticals jumps 14% as it moves toward accelerated FDA approval for mitapivat in sickle cell disease after key regulatory feedback.

Scholar Rock stock jumps 14% after it resubmits its FDA filing for SMA drug apitegromab, revives approval hopes and sets up a potential September 2026...

Scholar Rock stock jumps 14% after it resubmits its FDA filing for SMA drug apitegromab, revives approval hopes and sets up a potential September 2026...

Rocket Pharmaceuticals drops despite the FDA's accelerated approval of gene therapy Kresladi in severe leukocyte adhesion deficiency-I, an ultra-rare...

"CASGEVY Sales" Revolutionary CRISPR-Based Therapy Redefines Treatment Landscape for Sickle Cell Disease and Beta-Thalassemia with Strong Sales...

"CASGEVY Sales" Revolutionary CRISPR-Based Therapy Redefines Treatment Landscape for Sickle Cell Disease and Beta-Thalassemia with Strong Sales...

Corcept jumps after FDA approves Lifyorli combo for platinum-resistant ovarian cancer, marking the first-of-its-kind treatment.

United Therapeutics jumps 12.5% as phase III TETON-1 data show strong lung function gains for Tyvaso in IPF, paving the way for a potential FDA...

Ultragenyx Pharmaceutical jumps 5% as the FDA accepts UX111 BLA resubmission, setting up a September 2026 decision for a potential first treatment for...

Ultragenyx Pharmaceutical jumps 5% as the FDA accepts UX111 BLA resubmission, setting up a September 2026 decision for a potential first treatment for...